Abstract

Knockout (KO) mouse models play critical roles in elucidating biological processes behind disease-associated or disease-resistant traits. As a presumed consequence of gene KO, mice display certain phenotypes. Based on insight into the molecular role of said gene in a biological process, it is inferred that the particular biological process causally underlies the trait. This approach has been crucial towards understanding the basis of pathological and/or advantageous traits associated with Mertk KO mice. Mertk KO mice suffer from severe, early-onset retinal degeneration. MERTK, expressed in retinal pigment epithelia, is a receptor tyrosine kinase with a critical role in phagocytosis of apoptotic cells or cellular debris. Therefore, early-onset, severe retinal degeneration was described to be a direct consequence of failed MERTK-mediated phagocytosis of photoreceptor outer segments by retinal pigment epithelia. Here we report that the loss of Mertk alone is not sufficient for retinal degeneration. The widely used Mertk KO mouse carries multiple coincidental changes in its genome that affect the expression of a number of genes, including the Mertk paralog Tyro3. Retinal degeneration manifests only when the function of Tyro3 is concomitantly lost. Furthermore, Mertk KO mice display improved anti-tumor immunity. MERTK is expressed in macrophages. Therefore, enhanced anti-tumor immunity was inferred to result from the failure of macrophages to dispose of cancer cell corpses, resulting in a pro-inflammatory tumor microenvironment. The resistance against two syngeneic mouse tumor models observed in Mertk KO mice is not, however, phenocopied by the loss of Mertk alone. Neither Tyro3, nor macrophage phagocytosis by alternate genetic redundancy, account for the absence of anti-tumor immunity. Collectively, our results indicate that context-dependent epistasis of independent modifier alleles determines Mertk KO traits.

Data availability

RNA-sequencing data sets and the processed data that support the findings of this study have been deposited to the Gene Expression Omnibus (GEO) under accession ID: GSE205070. All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for all figures included.

The following data sets were generated

Article and author information

Author details

  1. Yemsratch T Akalu

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0829-7972
  2. Maria E Mercau

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6971-8676
  3. Marleen Ansems

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  4. Lindsey D Hughes

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1764-4553
  5. James Nevin

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  6. Emily J Alberto

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  7. Xinran N Liu

    Department of Cell Biology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  8. Li-Zhen He

    Celldex Therapeutics, New Haven, United States
    Competing interests
    Li-Zhen He, is affiliated with Celldex Therapeutics. The author has no financial interests to declare.
  9. Diego Alvarado

    Celldex Therapeutics, New Haven, United States
    Competing interests
    Diego Alvarado, is affiliated with Celldex Therapeutics. The author has no financial interests to declare..
  10. Tibor Keler

    Celldex Therapeutics, New Haven, United States
    Competing interests
    Tibor Keler, is affiliated with Celldex Therapeutics. The author has no financial interests to declare..
  11. Yong Kong

    Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2881-5274
  12. William M Philbrick

    Center on Endocrinology and Metabolism, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  13. Marcus Bosenberg

    Department of Dermatology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  14. Silvia C Finnemann

    Department of Biological Sciences, Fordham University, Bronx, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9298-0736
  15. Antonio Iavarone

    Department of Neurology, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  16. Anna Lasorella

    Department of Neurology, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  17. Carla V Rothlin

    Department of Immunobiology, Yale University, New Haven, United States
    For correspondence
    carla.rothlin@yale.edu
    Competing interests
    Carla V Rothlin, Senior editor, eLife.Is a scientific founder and member of the Scientific Advisory Board (SAB) of Surface Oncology, a member of Janessen Immuology SAB, and a consultant for the Roche Immunology Incubator. Has received grant support from Mirati Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5693-5572
  18. Sourav Ghosh

    Department of Neurology, Yale University, New Haven, United States
    For correspondence
    sourav.ghosh@yale.edu
    Competing interests
    Sourav Ghosh, has received grant support from Mirati Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5990-8708

Funding

National Institutes of Health (R01CA212376)

  • Carla V Rothlin
  • Sourav Ghosh

Howard Hughes Medical Institute

  • Carla V Rothlin

Yale Cancer Center (YSPORE Career Development Award DRP27)

  • Carla V Rothlin

Fordham University (Kim B. and Stephen E. Bepler Professorship in Biology)

  • Silvia C Finnemann

Dutch Cancer Society (BUIT 2012-5347)

  • Marleen Ansems

National Science Foundation (DGE-1122492)

  • Lindsey D Hughes

Yale University (Richard K. Gershon Fellowship)

  • Lindsey D Hughes

National Cancer Institute (2T32CA193200-06)

  • James Nevin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments involving animals were performed in accordance with regulatory guidelines and standards set by the Institutional Animal Care and Use Committee (IACUC) protocol (#2021-11312) of Yale University.

Copyright

© 2022, Akalu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,103
    views
  • 377
    downloads
  • 33
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yemsratch T Akalu
  2. Maria E Mercau
  3. Marleen Ansems
  4. Lindsey D Hughes
  5. James Nevin
  6. Emily J Alberto
  7. Xinran N Liu
  8. Li-Zhen He
  9. Diego Alvarado
  10. Tibor Keler
  11. Yong Kong
  12. William M Philbrick
  13. Marcus Bosenberg
  14. Silvia C Finnemann
  15. Antonio Iavarone
  16. Anna Lasorella
  17. Carla V Rothlin
  18. Sourav Ghosh
(2022)
Tissue-specific modifier alleles determine Mertk loss-of-function traits
eLife 11:e80530.
https://doi.org/10.7554/eLife.80530

Share this article

https://doi.org/10.7554/eLife.80530

Further reading

    1. Immunology and Inflammation
    2. Neuroscience
    Jeremy M Shea, Saul A Villeda
    Research Article

    During aging, microglia – the resident macrophages of the brain – exhibit altered phenotypes and contribute to age-related neuroinflammation. While numerous hallmarks of age-related microglia have been elucidated, the progression from homeostasis to dysfunction during the aging process remains unresolved. To bridge this gap in knowledge, we undertook complementary cellular and molecular analyses of microglia in the mouse hippocampus across the adult lifespan and in the experimental aging model of heterochronic parabiosis. Single-cell RNA-Seq and pseudotime analysis revealed age-related transcriptional heterogeneity in hippocampal microglia and identified intermediate states of microglial aging that also emerge following heterochronic parabiosis. We tested the functionality of intermediate stress response states via TGFβ1 and translational states using pharmacological approaches in vitro to reveal their modulation of the progression to an activated state. Furthermore, we utilized single-cell RNA-Seq in conjunction with in vivo adult microglia-specific Tgfb1 conditional genetic knockout mouse models to demonstrate that microglia advancement through intermediate aging states drives transcriptional inflammatory activation and hippocampal-dependent cognitive decline.

    1. Immunology and Inflammation
    Mohsen Khosravi-Maharlooei, Andrea Vecchione ... Megan Sykes
    Research Article

    Human immune system (HIS) mice constructed in various ways are widely used for investigations of human immune responses to pathogens, transplants, and immunotherapies. In HIS mice that generate T cells de novo from hematopoietic progenitors, T cell-dependent multisystem autoimmune disease occurs, most rapidly when the human T cells develop in the native NOD.Cg- Prkdcscid Il2rgtm1Wjl (NSG) mouse thymus, where negative selection is abnormal. Disease develops very late when human T cells develop in human fetal thymus grafts, where robust negative selection is observed. We demonstrate here that PD-1+CD4+ peripheral (Tph) helper-like and follicular (Tfh) helper-like T cells developing in HIS mice can induce autoimmune disease. Tfh-like cells were more prominent in HIS mice with a mouse thymus, in which the highest levels of IgG were detected in plasma, compared to those with a human thymus. While circulating IgG and IgM antibodies were autoreactive to multiple mouse antigens, in vivo depletion of B cells and antibodies did not delay the development of autoimmune disease. Conversely, adoptive transfer of enriched Tfh- or Tph-like cells induced disease and autoimmunity-associated B cell phenotypes in recipient mice containing autologous human APCs without T cells. Tfh/Tph cells from mice with a human thymus expanded and induced disease more rapidly than those originating in a murine thymus, implicating HLA-restricted T cell-APC interactions in this process. Since Tfh, Tph, autoantibodies, and lymphopenia-induced proliferation (LIP) have all been implicated in various forms of human autoimmune disease, the observations here provide a platform for the further dissection of human autoimmune disease mechanisms and therapies.